Treating Oncogenic Ras Driven Cancers
Oncogenic Ras-driven cancer is treated with agent by interrupting pathway comprising activation of Akt by oncogenic Ras, activated Akt causing phosphorylation of eNOS at S1177 site of eNOS to provide activated eNOS in cancer cells and activated eNOS causing activation of wildtype Ras by nitrosylation thereof at C118 to provide GTP -bound activated wildtype H and N Ras. L-NAME can be orally administered to interrupt this pathway. Wortmannin can be administered intravenously to interrupt this pathway. Novel siRNAs are disclosed useful to interrupt said pathway.
COUNTER CHRISTOPHER M [US]; LIM KIAN-HUAT [US]; ANCRILE BROOKE B [US]; KASHATUS DAVID F [US]
Type of Offer:
« More Biotech Patents